{"url_path":"/sec/asbp/8-k/2026-06-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-028386-index.html","accession_number":"0001493152-26-028386","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-028386-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":147,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n \n \n \n\n10.1*\n \n[Form of Purchase Agreement, dated June 10, 2026, by and among Aspire Biopharma Holdings, Inc. and FireFish TopCo, LLC](ex10-1.htm)\n\n \n \n \n\n99.1\n \n[Press\nRelease dated June 12, 2026.](ex99-1.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\nThe schedules, exhibits or similar attachments have been omitted from this filing pursuant to Item\n601(b)(2) of Regulation S-K. The Company will furnish copies of any schedules, exhibits or similar attachments to the Securities and\nExchange Commission upon request.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K\nto be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate:\nJune 12, 2026\n\n \n\nAspire\nBiopharma Holdings, Inc.\n \n\n \n \n \n\nBy:\n*/s/\nKraig T. Higginson*\n \n\nName:\n\nKraig\nT. Higginson\n \n\nTitle:\nChief Executive Officer and Chairman"}